TickerFacts.

Neumora Therapeutics, Inc. (NMRA): EPS (Basic)

Annual figures by period end, from SEC filings.

-$1.45
Year ended 2025-12-31
2022-12-31: -$4.812023-12-31: -$3.632024-12-31: -$1.532025-12-31: -$1.45-$1.45
2022-12-31 EPS (Basic) (USD per share) 2025-12-31
Period endedEPS (Basic)Change YoYSource filing
2025-12-31-$1.45n/m2026-03-30, From 2025-01-01
2024-12-31-$1.53n/m2026-03-30, From 2024-01-01
2023-12-31-$3.63n/m2025-03-03, From 2023-01-01
2022-12-31-$4.81n/a2025-03-03, From 2022-01-01

EPS (Basic) at similar companies

Companies with the same SEC industry code (Biological Products, (No Diagnostic Substances)), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedEPS (Basic)Change YoY
Neumora Therapeutics, Inc. (NMRA)2025-12-31-$1.45n/m
Editas Medicine, Inc. (EDIT)2025-12-31-$1.80n/m
Vaxart, Inc. (VXRT)2025-12-31$0.07n/m
Inhibikase Therapeutics, Inc. (IKT)2025-12-31-$0.49n/m
Instil Bio, Inc. (TIL)2025-12-31-$10.70n/m
Caribou Biosciences, Inc. (CRBU)2025-12-31-$1.59n/m
Protara Therapeutics, Inc. (TARA)2025-12-31-$1.34n/m
Sutro Biopharma, Inc. (STRO)2025-12-31-$22.49n/m
SAB Biotherapeutics, Inc. (SABS)2025-12-31$0.22n/m

Compare NMRA, EDIT, VXRT, IKT side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗